The lungs are the primary site of TB infection and disease. Understanding pulmonary involvement is crucial for diagnosis and treatment.

Upper Lobe Predominance: TB has a characteristic tendency to involve the upper lobes of the lungs, particularly the right upper lobe. This distribution relates to the higher oxygen tension in upper lung fields, as M. tuberculosis is an aerobic organism that thrives in well-oxygenated environments. Upper lobe involvement on chest X-ray is a key diagnostic feature.

Cavitary Lesions: As TB progresses, it destroys lung tissue, creating cavities—air-filled spaces within the lung that contain necrotic material and large numbers of bacteria. Cavities are highly significant because they serve as reservoirs of infection and are associated with greater infectiousness. The walls of these cavities are vascular, which is why hemoptysis (coughing blood) is a concerning symptom.

Pleural Involvement: The pleura (lining of the lungs) can be involved in TB, causing pleuritic chest pain—sharp pain worsened by breathing. Pleural effusion (fluid accumulation between lung and chest wall) occurs in some patients. Pleural TB usually results from rupture of a subpleural caseous focus into the pleural space.

Bronchial Spread: TB can spread through the bronchial tree, causing lesions in multiple lung lobes. This spread creates the characteristic radiographic pattern of patchy or lobar consolidation. Endobronchial TB can cause narrowing of airways, leading to collapse of lung segments (atelectasis).

The lymphatic system plays a central role in both the immune response to TB and the spread of infection.

Hilar and Mediastinal Lymphadenopathy: The lymph nodes at the hila of the lungs (where bronchi enter the lungs) and in the mediastinum (central chest) are commonly involved in primary TB. These nodes can enlarge significantly, sometimes compressing airways or causing symptoms.

Scrofula: Historically known as "the King's Evil," scrofula refers to TB infection of the cervical lymph nodes (neck glands). While less common today, it remains a manifestation of extrapulmonary TB. The nodes typically appear as painless, slowly enlarging masses that may eventually discharge creamy material through the skin.

Systemic Lymphatic Spread: The lymphatic system provides a pathway for TB to spread from the initial pulmonary focus to other parts of the body, contributing to the development of extrapulmonary TB.

TB can affect virtually any organ in the body when bacteria spread beyond the lungs. Extrapulmonary TB accounts for approximately 15-20% of TB cases in non-HIV patients and is more common in those with HIV or other immunocompromising conditions.

Lymph Nodes (Excluding Pulmonary): Beyond cervical nodes, TB can affect axillary, inguinal, and other peripheral lymph nodes. Presentation varies from single-node involvement to widespread lymphadenopathy.

Genitourinary System: Renal TB can cause symptoms mimicking urinary tract infections, eventually leading to kidney scarring and functional impairment. Genital TB in women can cause infertility, menstrual irregularities, and pelvic pain. In men, it can affect the prostate, epididymis, and testes.

Bones and Joints (Pott's Disease): Spinal TB (Pott's disease) is the most common form of skeletal TB, typically affecting the thoracic vertebrae. It can cause vertebral collapse, spinal curvature (kyphosis), and compression of the spinal cord with neurological complications.

Meninges (TB Meningitis): TB meningitis is one of the most severe forms of extrapulmonary TB, with high mortality and frequent neurological sequelae in survivors. It typically presents with gradual onset of headache, fever, and altered consciousness over weeks.

Pericardium (TB Pericarditis): TB can cause inflammation of the pericardium (the sac around the heart), leading to pericardial effusion (fluid accumulation). Constrictive pericarditis, where the pericardium becomes thickened and restricts heart filling, is a serious complication.

Abdomen (Abdominal TB): Can affect the peritoneal cavity, intestines, mesenteric lymph nodes, and solid organs. Presents with abdominal pain, ascites (fluid accumulation), and intestinal obstruction.

Understanding whether a person has latent TB infection or active TB disease is crucial for management, as the approaches differ significantly.

Latent TB Infection (LTBI): In latent TB, an individual has been infected with M. tuberculosis but the immune system is successfully containing the bacteria. There are no symptoms, the person is not infectious, and chest X-ray is typically normal. However, the bacteria remain dormant in the body and can reactivate to cause active disease if the immune system becomes compromised. Approximately 25% of the world's population (about 2 billion people) has latent TB, representing a vast reservoir of potential future disease.

Active TB Disease: When the immune system cannot control the infection, bacteria multiply actively, causing tissue damage and symptoms. Active TB is further classified by location.

Pulmonary TB: TB affecting the lungs and lower respiratory tract. This is the most common form and the only form that is typically infectious. Pulmonary TB is further categorized by radiographic findings and microbiological status.

Extrapulmonary TB: TB occurring in organs other than the lungs. While less common, extrapulmonary TB is more frequent in immunocompromised individuals, including those with HIV. It requires specific diagnostic approaches and treatment considerations.

Drug resistance in TB is a major public health concern that complicates treatment and worsens outcomes.

Drug-Susceptible TB: The standard form of TB that responds to first-line antibiotics (isoniazid, rifampicin, pyrazinamide, ethambutol). Treatment is relatively straightforward with cure rates exceeding 95% when medications are taken as prescribed.

Drug-Resistant TB (DR-TB): When TB bacteria develop the ability to survive despite antibiotic exposure. This occurs through genetic mutations that alter the bacterial targets of antibiotics or through drug-inactivating enzymes.

Multidrug-Resistant TB (MDR-TB): Defined as resistance to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs. MDR-TB requires treatment with second-line medications that are less effective, more toxic, and far more expensive. Treatment can take 18-24 months or longer.

Extensively Drug-Resistant TB (XDR-TB): A more severe form defined as MDR-TB plus resistance to any fluoroquinolone (such as levofloxacin or moxifloxacin) AND at least one of the second-line injectable drugs (amikacin, kanamycin, or capreomycin). XDR-TB is extremely difficult to treat and associated with very poor outcomes.

Rifampicin-Resistant TB (RR-TB): Resistance to rifampicin alone, which is often treated similarly to MDR-TB since rifampicin resistance usually accompanies other resistances.

Understanding how TB spreads is essential for prevention and infection control.

Airborne Transmission: TB is transmitted through airborne particles called droplet nuclei. When a person with active pulmonary TB coughs, sneezes, speaks, or sings, they expel these tiny particles (1-5 microns in diameter) that can remain suspended in air for extended periods. These particles are small enough to reach the alveoli (tiny air sacs) in the lungs when inhaled by another person.

Requirements for Transmission: Several factors influence whether transmission occurs:

• Infectiousness of the source: Patients with cavitary pulmonary TB and positive sputum smears are most infectious. Those with extrapulmonary TB or negative sputum are generally not infectious.
• Exposure duration: Brief, casual contact rarely transmits TB. Transmission typically requires prolonged close contact—living or working together, sharing sleeping quarters, or prolonged time in enclosed spaces.
• Ventilation: Poor ventilation allows droplet nuclei to accumulate. Good ventilation, UV light, and air filtration can reduce transmission risk.
• Immune status of the exposed person: Those with compromised immune systems are both more likely to develop disease if infected and may be more susceptible to initial infection.

Non-Transmission Routes: TB is NOT spread through:

• Handshaking or touching
• Sharing food or drinks
• Sharing bedding or clothing
• Swimming pools or public baths
• Sexual contact (except in rare cases of extrapulmonary genital TB)
• Kissing

The transition from infection to active disease involves complex interactions between the bacterium and the host immune system.

Primary Progression: Some individuals, particularly young children and those with severe immune compromise, develop active TB shortly after initial infection, within weeks or months. This "primary disease" often has different radiographic patterns than disease in previously infected adults.

Reactivation: The majority of people who develop active TB do so through reactivation of latent infection—bacteria that have persisted in a dormant state for months, years, or even decades before reactivating. Reactivation typically occurs when the immune system becomes compromised, allowing the dormant bacteria to resume multiplication.

Risk of Progression: Approximately 5-10% of people infected with M. tuberculosis will develop active TB at some point in their lifetime. The highest risk is in the first two years after infection, but reactivation can occur decades later if the immune system becomes impaired.

Certain conditions and characteristics significantly increase the risk of progressing from TB infection to active disease.

HIV Infection: HIV is the strongest known risk factor for TB. The risk of developing active TB in people living with HIV is 20-30 times higher than in HIV-negative individuals. HIV progressively depletes CD4+ T cells, which are essential for controlling M. tuberculosis infection. TB is a leading cause of death in people living with HIV worldwide.

Diabetes Mellitus: Diabetes increases the risk of active TB by 2-3 fold. The mechanism involves impaired innate and adaptive immune responses. People with diabetes also tend to have more severe TB disease and higher mortality. In regions with high diabetes prevalence like the UAE, this represents a significant driver of the TB epidemic.

Malnutrition: Protein-energy malnutrition and specific micronutrient deficiencies impair immune function. Weight loss and cachexia are hallmark features of advanced TB, creating a vicious cycle. Malnutrition is both a risk factor for progressing from infection to disease and a consequence of active disease.

Chronic Kidney Disease: Patients on hemodialysis have significantly elevated TB risk due to uremia-induced immune dysfunction. TB in these patients often presents with atypical features and higher mortality.

Silicosis: Silica dust exposure causes lung damage and impairs macrophage function. Workers in mining, construction, and sandblasting face elevated TB risk that persists even after exposure ends.

Immunosuppressive Medications: TNF-alpha inhibitors (used for rheumatoid arthritis, psoriasis, inflammatory bowel disease), high-dose corticosteroids, chemotherapy, and other immunosuppressants increase reactivation risk. Patients starting these medications should be screened for latent TB.

Young Age: Infants and young children have immature immune systems and higher risk of progressing to severe forms of TB, including TB meningitis and miliary TB, following initial infection.

Poverty and Crowding: TB has long been associated with poverty. Overcrowded housing, poor ventilation, and limited healthcare access facilitate both transmission and delayed diagnosis.

Substance Abuse: Alcohol use disorder and intravenous drug use increase TB risk through multiple mechanisms including direct immune suppression, poor nutrition, and increased exposure in social networks.

Healthcare Work: Healthcare workers face occupational exposure risk, particularly in high-burden settings or when performing aerosol-generating procedures without adequate protection.

Migration: Immigrants from high-burden countries may carry TB infection or disease. Travel to endemic areas increases exposure risk.

Active pulmonary TB typically presents with a characteristic constellation of symptoms that develop gradually over weeks to months.

Chronic Cough: A persistent cough lasting more than 2-3 weeks is the cardinal symptom of pulmonary TB. The cough is often productive, initially with white or clear sputum that may become blood-tinged or frankly bloody (hemoptysis) as disease progresses. Hemoptysis usually indicates cavitary disease with erosion into blood vessels.

Systemic Symptoms:

• Fatigue: Profound, progressive tiredness that interferes with daily activities
• Weight loss: Unintentional weight loss, often significant (5-10% of body weight), giving rise to the historical name "consumption"
• Low-grade fever: Typically present in the afternoon or evening, often accompanied by chills
• Night sweats: Drenching night sweats that may soak bedclothes, though this symptom is less specific than previously thought

Additional Symptoms:

• Chest pain, often pleuritic (sharp, worse with deep breathing or coughing)
• Loss of appetite
• Shortness of breath (with extensive disease)
• Hoarseness (if larynx is involved)

TB can present differently in certain populations, leading to delayed diagnosis.

Elderly: May present with nonspecific symptoms like confusion, weakness, or failure to thrive rather than classic respiratory symptoms.

People with HIV: More likely to have extrapulmonary or disseminated disease. May have atypical chest X-ray findings including lower lobe involvement or diffuse infiltrates.

Children: Often have paucibacillary disease (few bacteria), making diagnosis difficult. May present with failure to thrive, fever, or respiratory symptoms without classic adult presentations.

Symptoms depend entirely on the organ system involved.

Lymphadenopathy: Painless enlargement of lymph nodes, often cervical (scrofula)

Bone and Joint Pain: Back pain (spine), joint pain or swelling (knees, hips)

Genitourinary: Dysuria, flank pain, hematuria (kidney); pelvic pain, infertility (genital)

Meningeal: Headache (progressive), neck stiffness, photophobia, altered consciousness

Pericardial: Chest pain, shortness of breath, signs of heart failure (pericardial effusion)

TB is a systemic infection affecting the entire body, not just the lungs.

Cachexia: The profound weight loss and muscle wasting in TB results from a combination of reduced nutrient intake (anorexia, catabolism from chronic infection), increased metabolic demands, and cytokine-mediated muscle breakdown. This cachexia persists even with adequate caloric intake until the infection is treated.

Anemia: Chronic disease anemia is common in TB, resulting from reduced red blood cell production, iron sequestration, and possible blood loss (especially with hemoptysis). Anemia contributes to fatigue and exercise intolerance.

Fever Pattern: The characteristic low-grade fever often peaks in the late afternoon or evening. Fever may be intermittent or continuous and usually resolves with effective treatment.

Bronchiectasis: Permanent widening of airways from chronic inflammation and destruction of bronchial walls. Causes chronic cough, sputum production, and recurrent infections.

Emphysema: Destruction of lung tissue reducing respiratory function.

Pneumothorax: Cavitary disease can rupture into the pleural space, causing lung collapse. This is a medical emergency.

Cor Pulmonale: Chronic lung damage can lead to right heart failure as the heart struggles to pump blood through damaged pulmonary vessels.

Secondary Infections: Damaged lung tissue is susceptible to bacterial pneumonia, fungal infections, and other opportunistic infections.

A thorough clinical assessment is essential for TB diagnosis and management.

Symptom Characterization:

• Onset and duration of cough, weight loss, fever, night sweats
• Progression of symptoms over time
• Sputum production, character, and presence of blood
• Associated symptoms including chest pain, shortness of breath, fatigue

Exposure History:

• Known contact with TB patient
• Country of origin and travel history
• Previous TB diagnosis or treatment
• Living conditions, occupation, and potential exposures

Medical History:

• HIV status and other immunocompromising conditions
• Diabetes mellitus
• Chronic kidney disease
• Previous surgeries (especially organ transplants)
• Current medications, especially immunosuppressants

Social History:

• Smoking status and history
• Alcohol and substance use
• Occupation (healthcare, mining, etc.)
• Recent immigration from endemic country

General Appearance: Cachexia, pallor (from anemia), fever, tachycardia

Chest Examination: May reveal crackles over affected lung fields, especially in upper lobes. Diminished breath sounds with pleural effusion. Signs of cavitation may include amphoric breath sounds (hollow, echoing quality).

Lymph Nodes: Check for cervical, supraclavicular, and axillary lymphadenopathy

Other Systems: Based on suspected extrapulmonary involvement

Sputum Smear Microscopy: The most widely available test. Sputum is stained for acid-fast bacilli (AFB) and examined under a microscope. Results available within hours, but cannot distinguish M. tuberculosis from nontuberculous mycobacteria and has limited sensitivity (especially in paucibacillary disease).

Sputum Culture: The gold standard for TB diagnosis. Culture allows definitive identification of M. tuberculosis and drug susceptibility testing. However, culture takes 1-6 weeks due to the slow growth of TB bacteria. Liquid culture systems (like BACTEC) are faster than solid media.

GeneXpert MTB/RIF: A rapid molecular test that detects M. tuberculosis DNA and rifampicin resistance simultaneously within 2 hours. Recommended as the initial test for anyone suspected of pulmonary TB. Does not require a laboratory with high biosafety infrastructure.

Line Probe Assays: Molecular tests that can detect M. tuberculosis complex and resistance to multiple drugs. Useful for rapid screening of smear-positive specimens.

Drug Susceptibility Testing (DST): Essential for guiding treatment in areas with drug resistance. Can be performed on culture isolates or directly on specimens.

Chest X-Ray: A crucial diagnostic tool with characteristic findings:

• Upper lobe infiltrates or cavitation
• Hilar or mediastinal lymphadenopathy
• Pleural effusion
• Miliary pattern (tiny nodules throughout lungs) in disseminated disease

Findings may differ in people with HIV, who more commonly have lower lobe or diffuse infiltrates or normal chest X-rays despite active disease.

CT Scan: Provides detailed images of lung parenchyma and mediastinum. More sensitive than X-ray for detecting subtle findings, cavitation, and lymphadenopathy.

Tuberculin Skin Test (TST): Also known as the Mantoux test. A small amount of TB protein (tuberculin) is injected intradermally, and the induration (raised, hard area) is measured after 48-72 hours. Indicates TB infection but cannot distinguish between latent and active disease. Can be false-negative in early infection, severe disease, or immunosuppression.

Interferon-Gamma Release Assays (IGRAs): Blood tests (like QuantiFERON-TB Gold Plus and T-SPOT.TB) that measure T-cell release of interferon-gamma in response to TB-specific antigens. More specific than TST (less cross-reaction with BCG vaccination and most nontuberculous mycobacteria). Cannot distinguish latent from active TB.

HIV Testing: Recommended for all TB patients due to the strong association. Co-management of HIV and TB is essential for optimal outcomes.

Additional Tests: Complete blood count, liver function tests, renal function tests, and electrolytes help assess overall health and medication toxicity risk.

First-Line Antitubercular Drugs: The standard regimen uses four drugs for the initial phase and two drugs for the continuation phase.

Standard 6-Month Regimen:

• Intensive Phase (2 months): Isoniazid, rifampicin, pyrazinamide, ethambutol
• Continuation Phase (4 months): Isoniazid, rifampicin

Directly Observed Therapy (DOT): To ensure treatment completion, the World Health Organization recommends DOT, where a healthcare worker or trained volunteer observes each dose being taken. DOT significantly improves cure rates and reduces treatment failure and relapse.

Purpose: To prevent progression from latent infection to active disease in high-risk individuals.

MDR-TB and XDR-TB require specialized treatment with second-line drugs that are less effective, more toxic, and more expensive. Treatment should be managed by specialists in drug-resistant TB. Newer drugs including bedaquiline, delamanid, and pretomanid have improved outcomes for MDR-TB.

Homeopathic treatment for TB focuses on constitutional support during the prolonged treatment period and recovery phase. Constitutional remedies are selected based on the patient's complete symptom picture, including physical constitution, emotional state, and miasmatic tendencies. Treatment aims to:

• Support overall vitality during antibiotic treatment
• Address the deep cachexia and weakness
• Help manage medication side effects
• Strengthen respiratory system
• Support recovery and tissue healing

Ayurvedic protocols for TB (known as "Rajayakshma" in classical texts) focus on comprehensive restoration:

• Dietary Support: Easily digestible, nutritious foods to address cachexia
• Herbal Preparations: Herbs supporting respiratory health including Vasaka (Adhatoda), Licorice, and Turmeric
• Rasayana Therapy: Rejuvenation treatments to restore vitality and tissue health
• Panchakarma: Purification therapies when appropriate for the patient's constitution
• Lifestyle Guidance: Breathing exercises (Pranayama), gentle yoga, and restful routines
• Immune Support: Building Ojas (vital essence) through diet and lifestyle

TB causes significant nutritional depletion through multiple mechanisms. IV nutrition addresses:

• Protein: For muscle wasting and tissue repair
• Vitamin D: Immune modulation and bone health
• Zinc: Immune function and wound healing
• Vitamin C: Antioxidant support and immune function
• B-Complex Vitamins: Energy metabolism and nerve health
• Iron: Addressing anemia if present
• Magnesium: Muscle function and metabolic support

Advanced energetic screening provides insights into:

• Organ system function and stress patterns
• Energetic patterns related to respiratory function
• Nutritional status indicators
• Treatment response guidance

Absolute Requirements:

• Take all medications exactly as prescribed—no missed doses
• Complete the entire course of treatment, even if feeling better
• Regular follow-up appointments for monitoring
• Report any side effects promptly

Strategies for Adherence:

• Use a pill organizer or alarm reminders
• Integrate medication into daily routine
• Keep a treatment diary
• Seek support from family and healthcare providers

During Infectious Period:

• Cover coughs and sneezes with tissue or elbow
• Dispose of tissues properly
• Sleep in separate room if possible
• Ensure good ventilation in living spaces
• Wear a mask when around others, especially in first weeks
• Limit visitors until non-infectious

After Becoming Non-Infectious:

• Usually after 2-3 weeks of effective treatment
• Continue good hygiene practices
• Maintain adequate ventilation

Nutrition:

• Eat small, frequent, nutrient-dense meals
• Focus on protein (eggs, fish, chicken, legumes)
• Include colorful fruits and vegetables for antioxidants
• Stay well-hydrated

Rest:

• Prioritize adequate sleep (8+ hours)
• Rest during the day as needed
• Gradually increase activity as strength returns
• Avoid strenuous activity during intensive treatment

Mental Health:

• TB treatment is lengthy—prepare for the journey
• Seek support from family, friends, or support groups
• Address any stigma or isolation
• Consider counseling if feeling overwhelmed

Vaccination: BCG (Bacillus Calmette-Guérin) vaccine provides variable protection against severe forms of TB (meningeal, miliary) in children. Protection against pulmonary TB in adults is variable (0-80%). Not typically recommended in low-burden settings like the UAE.

Screening and Treatment of Latent TB: Testing for latent TB is recommended for high-risk individuals (contacts of active cases, people with HIV, those starting immunosuppressants). Treatment of latent TB prevents progression to active disease.

Infection Control:

• Avoid close contact with known TB patients
• If exposure is unavoidable, ensure good ventilation
• Healthcare workers should use appropriate respiratory protection

General Health:

• Control underlying conditions (diabetes, HIV)
• Maintain good nutrition
• Avoid smoking
• Manage stress

Case Finding: Active case finding in high-risk populations, contact tracing, and screening of high-risk groups.

Treatment Completion: DOT programs ensure patients complete treatment, preventing chronic disease, relapse, and drug resistance.

Infection Control in Healthcare Settings: Proper isolation of suspected cases, respiratory protection for healthcare workers, and environmental controls (UV germicidal irradiation, negative pressure rooms).

Cure Rates: With proper treatment of drug-susceptible TB, cure rates exceed 95%. Most patients become non-infectious within 2-3 weeks of starting effective treatment.

Timeline: Clinical improvement usually begins within weeks, but radiographic resolution takes months. Treatment completion (6-9 months) is essential to prevent relapse.

Return to Health: Most patients make a full recovery with return to normal activities. Some may have residual lung damage visible on imaging, but this often does not cause significant functional impairment.

Mortality: Without treatment, approximately 50% of patients with active pulmonary TB die within 5 years. Death is usually from progressive pulmonary destruction, massive hemoptysis, or respiratory failure.

Spread: Untreated patients remain infectious, potentially infecting 10-15 others per year through close contact.

Drug Resistance: Inadequate treatment can lead to drug-resistant TB, which is much more difficult and expensive to treat.

Post-Treatment:

• Most patients return to full health
• Some may have chronic respiratory symptoms (cough, shortness of breath)
• Lung damage may predispose to future respiratory infections
• Follow-up is important, especially in first year after treatment

Q: Is TB curable?

A: Yes, TB is curable with proper antibiotic treatment. The standard 6-9 month regimen cures over 95% of drug-susceptible TB cases. The key is completing the full course of treatment exactly as prescribed. Stopping treatment early, even when feeling better, risks treatment failure, relapse, and development of drug-resistant TB.

Q: How is TB spread?

A: TB is spread through airborne particles called droplet nuclei when someone with active pulmonary TB coughs, sneezes, speaks, or sings. Close, prolonged contact is usually required for transmission—brief casual contact rarely transmits TB. TB is NOT spread by shaking hands, sharing food or drinks, touching shared surfaces, or sexual contact (with rare exceptions).

Q: What is the difference between latent TB and active TB?

A: Latent TB means you have TB bacteria in your body but your immune system is keeping them under control—you have no symptoms and cannot spread TB to others. Approximately 25% of the world's population has latent TB. Active TB means your immune system cannot control the bacteria, you have symptoms, and you can spread TB to others. Latent TB can be treated to prevent progression to active TB.

Q: Can TB come back after treatment?

A: TB can recur, usually due to either re-infection (a new infection) or relapse (the original infection wasn't fully cleared). Completing treatment properly is the best prevention. Those who have been successfully treated can still get TB again if re-exposed to the bacteria.

Q: What is drug-resistant TB?

A: Drug-resistant TB occurs when the bacteria develop the ability to survive despite antibiotics. This happens when treatment is incomplete or incorrect, allowing bacteria with resistance mutations to survive and multiply. MDR-TB (multi-drug resistant) requires much longer, more expensive treatment with drugs that are less effective and more toxic. Prevention through proper treatment is critical.

Q: How long is someone with TB infectious?

A: With effective treatment, most patients become non-infectious within 2-3 weeks. This is typically assessed by symptom improvement and sputum smear conversion (no more AFB on microscopy). However, treatment must continue for the full course to achieve cure.

Q: Can I work while being treated for TB?

A: This depends on the nature of your work and whether you are infectious. People with active pulmonary TB should not work until they are no longer infectious, typically 2-3 weeks after starting effective treatment. Those with extrapulmonary TB can usually continue working. Your healthcare provider and public health authority will provide guidance based on your specific situation.

Q: What should I do if I've been exposed to TB?

A: If you've had close, prolonged contact with someone with active TB, you should be evaluated for TB infection. This typically involves a tuberculin skin test (TST) or interferon-gamma release assay (IGRA) blood test. If you have latent TB infection, preventive treatment is usually recommended to prevent progression to active disease, especially if you have risk factors like HIV or recent infection.

Last Updated: March 2026 Healers Clinic - Transformative Integrative Healthcare Serving patients in Dubai, UAE and the GCC region since 2016